Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.

Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM.

Pharm Res. 2013 Mar;30(3):655-69. doi: 10.1007/s11095-012-0894-2. Epub 2012 Dec 19.

PMID:
23250851
2.

Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Yang BB, Doshi S, Arkam K, Franklin J, Chow AT.

Clin Pharmacokinet. 2016 Sep;55(9):1045-58. doi: 10.1007/s40262-016-0382-7. Review.

PMID:
27056734
3.

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT.

AAPS J. 2010 Dec;12(4):729-40. doi: 10.1208/s12248-010-9234-9. Epub 2010 Oct 21.

4.

Romiplostim dose-response in patients with myelodysplastic syndromes.

Perez Ruixo JJ, Doshi S, Wang YM, Mould DR.

Br J Clin Pharmacol. 2013 Jun;75(6):1445-54. doi: 10.1111/bcp.12041.

5.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
6.

Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.

Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN.

Pharm Res. 2011 Aug;28(8):1931-8. doi: 10.1007/s11095-011-0420-y. Epub 2011 Apr 8.

PMID:
21476045
7.

Development of romiplostim: a novel engineered peptibody.

Yang AS.

Semin Hematol. 2015 Jan;52(1):12-5. doi: 10.1053/j.seminhematol.2014.10.007. Epub 2014 Oct 31. Review.

PMID:
25578414
8.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.

9.

Romiplostim: a novel thrombopoiesis-stimulating agent.

Perreault S, Burzynski J.

Am J Health Syst Pharm. 2009 May 1;66(9):817-24. doi: 10.2146/ajhp080524. Review.

PMID:
19386944
10.

Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.

Krzyzanski W, Perez-Ruixo JJ, Harrold J.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):709-20. doi: 10.1007/s10928-015-9440-2. Epub 2015 Sep 4.

PMID:
26341875
11.

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.

Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U.

Br J Haematol. 2014 Nov;167(3):337-45. doi: 10.1111/bjh.13037. Epub 2014 Jul 14.

PMID:
25039607
12.

Romiplostim for the treatment of primary immune thrombocytopenia.

Janssens A.

Expert Rev Hematol. 2012 Apr;5(2):133-44. doi: 10.1586/ehm.12.6.

PMID:
22475281
13.

Romiplostim dose response in patients with immune thrombocytopenia.

Perez-Ruixo JJ, Green B, Doshi S, Wang YM, Mould DR.

J Clin Pharmacol. 2012 Oct;52(10):1540-51. Epub 2011 Dec 13.

PMID:
22167563
14.

Romiplostim for management of chemotherapy-induced thrombocytopenia.

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Support Care Cancer. 2014 May;22(5):1217-22. doi: 10.1007/s00520-013-2074-2. Epub 2014 Jan 12.

PMID:
24414994
15.

Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.

Samtani MN, Perez-Ruixo JJ, Brown KH, Cerneus D, Molloy CJ.

J Clin Pharmacol. 2009 Mar;49(3):336-50. doi: 10.1177/0091270008329559.

PMID:
19246731
16.
17.

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL.

Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Epub 2008 Nov 3. Erratum in: Blood. 2009 May 7;113(19):4822.

18.

Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.

Hartranft ME, Clemmons AB, DeRemer DL, Kota V.

J Oncol Pharm Pract. 2017 Jan;23(1):10-17. doi: 10.1177/1078155215612240. Epub 2016 Jun 22.

PMID:
26471738
19.

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.

Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5.

PMID:
26537623
20.

Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.

Matsuki E, Miyakawa Y, Yamane A, Okamoto S.

Exp Hematol. 2011 Aug;39(8):829-36. doi: 10.1016/j.exphem.2011.05.001. Epub 2011 May 7.

PMID:
21605620

Supplemental Content

Support Center